Selected matrix metalloproteinases (MMP-2, MMP-9) in obese children and adolescents;Ocena stȩżenia wybranych metaloproteinaz macierzy zewna̧trzkomórkowej (MMP-2, MMP-9) u dzieci i młodzieży z otyłościa̧ prosta̧

Endokrynologia, Diabetologia i Choroby Przemiany Materii Wieku Rozwojowego

Volumn 12, Issue 3, 2006, Pages 179-183

  Głowińska Olszewska, Barbara ^a   Urban, Mirosława ^a   Florys, Bozena ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Children; Matrix metalloproteinases MMP 2; MMP 9; Obesity

Indexed keywords

GELATINASE A; GELATINASE B; BIOLOGICAL MARKER;

ADOLESCENT; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; OBESITY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; ATHEROSCLEROSIS; BLOOD; BODY MASS; FEMALE; MALE; REFERENCE VALUE;

ADOLESCENT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BODY MASS INDEX; CHILD; FEMALE; HUMANS; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; OBESITY; REFERENCE VALUES;

EID: 33749475732     PISSN: 1234625X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Beaudeux J.L., Giral P., Bruckert E. i wsp.: Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin. Chem. Lab. Med., 2004, 42, 121-131.
2. Jacob M.P., Badier-Commander C., Fontaine V. i wsp.: Extracellular matrix remodeling in the vascular wall. Pathol. Biol. (Paris), 2001, 49, 326-332.
3. Jones C.B., Sane D.C., Herrington D.M.: Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc. Res., 2003, 59, 812-823.
4. Ferroni P., Basili S., Martini F. i wsp.: Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J. Investig. Med., 2003, 51, 295-300.
5. Nomoto K., Oguchi S., Watanabe I. i wsp.: Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1. J. Cardiol., 2003, 42, 201-206.
6. Ross R.: Atherosclerosis - an inflammatory disease. N. Engl. J. Med., 1999, 340, 115-126.
7. Galis Z.S., Khatri J.J.: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res., 2002, 90, 251-262.
8. Christoffel K.K., Ariza A.: The epidemiology of overweight in children: relevance for clinical care. Pediatrics, 1998, 101, 103-105.
9. Freedman D.S., Khan L.K., Dietz W.H. i wsp.: Relationship of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart Study. Pediatrics, 2001, 108, 712-718.
10. Must A., Strauss R.S.: Risks and consequences of childhood and adolescent obesity. Int. J. Obes. Relat. Metab. Disord., 1999, 23, supl. 2, S2-11.
11. Eriksson J.G., Forsen T., Tuomilehto J. i wsp.: Catch-up growth in childhood and death from coronary heart disease: longitudinal study. BMJ, 1999, 318, 427-431.
12. Must A., Jacques P.F., Dallal G.E. i wsp.: Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N. Engl. J. Med., 1992, 327, 1350-1355.
13. Radziuk J: Insulin sensivity and its measurement structural commonalities among the methods. J. Clin. Endocrinol. Metab., 2000, 85, 4426-4433.
14. Laimer M., Kaser S., Kranebitter M. i wsp.: Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int. J. Obes. (Lond.), 2005, 29, 498-501.
15. Ghanim H., Aljada A., Hofmeyer D. i wsp.: Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation, 2004, 110, 1564-1571.
16. Chavey C., Mari B., Monthouel M.N. i wsp.: Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J. Biol. Chem., 2003, 278, 11888-11896.
17. Lijnen H.R., Maquoi E., Demeulemeester D. i wsp.: Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity. Thromb. Haemost., 2002, 88, 345-353.
18. Wilson D., Massaeli H., Russell J.C. I wsp.: Low matrix metalloproteinase levels precede vascular lesion formation in the JCR:LA-cp rat. Mol. Cell. Biochem., 2003, 249, 151-155.
19. Ahmed S.H., Clark L.L., Pennington W.R. i wsp.: Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation, 2006, 113, 2089-2096.
20. Papadopoulos D.P., Makris T.K., Krespi P.G. i wsp.: Changes in metalloproteinases in healthy normotensive patients with high-normal blood pressure. Eur. Cytokine Netw., 2005, 16, 211-214.
21. Tayebjee M.H., Nadar S., Blann A.D. i wsp.: Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am. J. Hypertens., 2004, 17, 764-769.
22. Ergul A., Portik-Dobos V., Hutchinson J. i wsp.: Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients. Am. J. Hypertens., 2004, 17, 775-782.
23. Zervoudaki A., Economou E., Stefanadis C. i wsp.: Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J. Hum. Hypertens., 2003, 17, 119-124.
24. Malik J., Stulc T., Ceska R.: Matrix metalloproteinases in isolated hypercholesterolemia. Int. Angiol., 2005, 24, 300-303.
25. Beaudeux J.L., Giral P., Bruckert E. i wsp.: Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis, 2003, 169, 139-146.
26. Blankenberg S., Rupprecht H.J., Poirier O. i wsp.: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation, 2003, 107, 1579-1585.
27. Noji Y., Kajinami K., Kawashiri M.A. i wsp.: Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin. Chem. Lab. Med., 2001, 39, 380-384.
28. Death A.K., Fisher E.J., McGrath K.C., Yue D.K.: High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis, 2003, 168, 263-269.
29. Uemura S., Matsushita H., Li W. i wsp.: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ. Res., 2001, 88, 1291-1298.